AKT1 and prostate carcinoma: Zhang et al. suggest that LTBP2 is not only a promising diagnostic biomarker for biochemical recurrence of prostate cancer but also plays a significant role in regulating the immune microenvironment, affecting responses to immunotherapy, and inhibiting cancer cell proliferation and metastasis through the PI3K/AKT signaling pathway31.